Core Insights - McKesson Corporation (MCK) reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $9.34, exceeding the Zacks Consensus Estimate of $9.31 by 0.3%, and reflecting a year-over-year improvement of 16.3% driven by strong operational growth and acquisitions in the Oncology & Multispecialty segment [1][7] Revenue Details - Revenues reached $106.16 billion, surpassing the Zacks Consensus Estimate by 0.5%, and increased by 11.4% year over year, primarily due to higher prescription volumes from retail national account customers and growth in oncology and specialty product distribution [2][7] - The North American Pharmaceutical segment generated revenues of $88.3 billion, up 9% year over year, attributed to increased prescription volumes and specialty products [5] Segmental Analysis - The Oncology & Multispecialty segment reported revenues of $13 billion, a significant increase of 37% year over year, driven by growth in provider solutions and specialty distribution, along with contributions from acquisitions [8] - The Prescription Technology Solutions segment's revenues totaled $1.5 billion, up 9% year over year, supported by increased prescription volumes in third-party logistics and technology services [9] - The Medical-Surgical Solutions segment generated revenues of $3 billion, a modest increase of 1% year over year, with adjusted operating profit down 10% due to reduced volumes in physician office settings [10] Financial Performance - Adjusted gross profit was $3.66 billion, reflecting a year-over-year increase of 9.6%, while adjusted operating income rose 13.4% to $1.81 billion, with an operating margin of 1.9%, expanding nearly 22 basis points year over year [11] - Cash and cash equivalents stood at $2.96 billion, down from $4 billion in the previous quarter, with cumulative net cash provided by operating activities amounting to $2.73 billion [12] Fiscal 2026 Guidance - McKesson raised its EPS guidance for fiscal 2026 to a range of $38.80-$39.20 from the previous $38.35-$38.85, and expects total revenue growth of 12-16%, up from the prior guidance of 11-15% [13][16] Strategic Developments - The company is progressing towards the spin-off of its Medical-Surgical Solutions business, expected to be completed by the second half of calendar 2027, and has divested its retail and distribution businesses in Norway, marking its exit from European operations [15]

Core Viewpoint - Concerns over growth and weak labor market data have led to significant declines in the U.S. stock market, with the S&P 500 index turning negative for the year [2][3][4]. Group 1: Market Performance - The Dow Jones Industrial Average fell nearly 600 points, a decline of approximately 1.2% [3]. - The S&P 500 index also dropped by 1.2%, marking a year-to-date downturn [3]. - The Nasdaq Composite Index decreased by 1.6%, continuing its most severe decline since April of the previous year [4]. Group 2: Sector Performance - Technology stocks and speculative bets on Wall Street experienced renewed declines, with the information technology sector of the S&P 500 falling by 1.7% [4]. - Software stocks saw significant drops, with Microsoft down 5% and Salesforce down 4.7% [4]. - The consumer discretionary sector faced severe losses, with DoorDash down 6.1% and both Lululemon and Ralph Lauren down over 4% [3]. Group 3: Individual Company Performance - Estée Lauder's stock plummeted by 19%, the largest decline among S&P 500 constituents, due to anticipated profit reductions of about $100 million related to tariffs [5]. - Cummins, an engine manufacturer, saw its stock drop by 11%, marking its largest single-day percentage decline since the onset of the COVID-19 pandemic [5]. - McKesson, a diversified healthcare services company, reported strong earnings, leading to a 17% increase in its stock price, the highest gain in the S&P 500 index [5]. Group 4: Commodity and Cryptocurrency Performance - Bitcoin fell by 13%, contributing to a 19% drop in the stock price of cryptocurrency firm Coinbase, marking its 13th consecutive day of decline [4]. - Silver prices decreased by 9.1% [4].

Market Overview - U.S. equities faced a challenging day on February 5, 2026, with significant sell-offs in technology stocks and negative job market reports impacting investor sentiment [1] - The S&P 500 fell 1.2% to close at 6,798.40, marking its sixth decline in seven trading days since reaching an all-time high [2] - The Nasdaq Composite dropped 1.6% to 22,540.59, while the Dow Jones Industrial Average decreased by 1.2% to 48,908.72 [2] - Bitcoin prices fell below $64,000, reaching their lowest level since October 2024, further exacerbating the downturn [2] Major Market Movers and Corporate News - Alphabet (GOOGL) saw a decline of 0.8% despite stronger-than-expected sales, as investors were concerned about projected capital expenditures for AI infrastructure, estimated at $175 billion to $185 billion for 2026, nearly double the $91.45 billion spent in 2025 [3] - Qualcomm (QCOM) experienced an 8.5% drop due to a disappointing outlook, citing a tightening global memory shortage affecting the smartphone market [4] - Advanced Micro Devices (AMD) fell sharply by 17.3% on a weak outlook, contributing to the semiconductor sector's struggles [4] - Uber Technologies (UBER) declined by 5.2% after missing earnings expectations, while Amgen (AMGN) surged 8.2% on positive earnings results [5] - Eli Lilly (LLY) jumped 10.3% due to strong sales of its drugs, and McKesson (MCK) soared 16.5% after exceeding profit and revenue expectations [5] - Peloton Interactive (PTON) plummeted 28% after reporting weaker-than-expected results, while Estee Lauder (EL) and Snap (SNAP) retreated by 19% and 12%, respectively [6] Job Market Developments - Amazon (AMZN) announced plans to cut approximately 16,000 corporate roles, while UPS revealed 30,000 job cuts [7] - Dow (DOW) reduced its workforce by 4,500 jobs, with Home Depot (HD) and Nike (NKE) also making cuts [7] Economic Indicators - Initial jobless claims for the week ending January 31 rose to 231,000, exceeding economists' estimates [9] - U.S. employers announced over 108,000 layoffs in January, the highest for that month since 2009, with job openings falling to 6.5 million in December, the lowest since 2020 [9] - The Consumer Price Index rose 2.7% over the year in December, indicating persistent inflation despite potential interest rate cuts by the Federal Reserve [10] Upcoming Market Events - Investors are awaiting the release of January U.S. Non-Farm Payrolls, Unemployment Rate, and Average Hourly Earnings data on February 6, which will provide further insights into the labor market [8]

Core Viewpoint - McKesson Corporation's shares have surged approximately 16 percent in morning trading, reaching $956.61, attributed to the positive impact of its recent third-quarter financial results announcement [1][2]. Group 1: Stock Performance - McKesson's shares are currently trading at $956.61, reflecting an increase of 16.27 percent or $133.76 [1]. - The stock opened at $867.97 and has peaked at $964.94 during the trading session [1]. - Over the past year, McKesson's stock has fluctuated between $570.51 and $964.94 [1]. Group 2: Financial Results - The company's third-quarter earnings rose to $1.186 billion, equating to $9.59 per share, compared to $879 million or $6.95 per share in the previous year [2].

Core Insights - McKesson reported consolidated revenue of $106.2 billion, reflecting an 11% year-over-year growth, attributed to strong performance across various segments, including higher prescription volumes and contributions from recent acquisitions [1][3]. Financial Performance - The company achieved record quarterly revenue and adjusted operating profit, with double-digit growth in adjusted operating profit in Oncology, Multispecialty, and Biopharma Services [2][3]. - For fiscal 2026, McKesson raised its earnings per diluted share guidance to $38.80 to $39.20, indicating a year-over-year growth of 17% to 19% [2][3]. - Gross profit increased by 10% to $3.7 billion, while operating expenses rose by 7% to $2.1 billion, resulting in a 138 basis point improvement in operating expenses as a percentage of gross profit [6][7]. Segment Performance - Oncology and Multispecialty revenue surged by 37% to $13 billion, driven by provider growth and expanded specialty distribution [5][9]. - North American Pharmaceutical revenue reached $88.3 billion, up 9%, supported by higher prescription volumes [8]. - GLP-1 distribution revenue was $14 billion, marking a 26% increase year-over-year [5][8]. Cash Flow and Capital Deployment - McKesson generated $1.1 billion in free cash flow for the quarter and $9.6 billion for the trailing twelve months, attributed to strong operational performance [4][18]. - The company returned $781 million to shareholders during the quarter, including $680 million in share repurchases [4][19]. Strategic Initiatives - McKesson is progressing towards an IPO of its Medical-Surgical business by the second half of 2027 [4][13]. - The company completed the divestiture of its retail and distribution businesses in Norway, marking its exit from Europe [14]. - Investments in automation and AI-driven capabilities are enhancing operational efficiency and productivity [6][16]. Regulatory Environment - The company is actively managing the implications of the Inflation Reduction Act's Medicare Part D price changes, viewing the policy landscape as manageable [17].

Core Insights - McKesson reported revenue of $106.16 billion for the quarter ended December 2025, reflecting an 11.4% increase year-over-year and surpassing the Zacks Consensus Estimate of $105.66 billion by 0.47% [1] - The company's EPS for the quarter was $9.34, up from $8.03 in the same quarter last year, also exceeding the consensus EPS estimate of $9.31 by 0.35% [1] Revenue Performance - Medical-Surgical Solutions revenue was $2.99 billion, slightly below the average estimate of $3.05 billion, with a year-over-year increase of 1.4% [4] - Prescription Technology Solutions revenue matched the average estimate at $1.5 billion, showing a year-over-year growth of 9.4% [4] - Other revenue reached $335 million, exceeding the estimated $297.61 million [4] - North American Pharmaceutical revenue was $88.32 billion, slightly below the average estimate of $88.6 billion, with a year-over-year increase of 1.4% [4] - Oncology & Multispecialty revenue was $13.01 billion, surpassing the average estimate of $12.48 billion [4] Adjusted Operating Profit - Adjusted Operating Profit for Medical-Surgical Solutions was $265 million, below the estimate of $278.29 million [4] - Adjusted Operating Profit for Prescription Technology Solutions was $277 million, exceeding the average estimate of $264.4 million [4] - Adjusted Operating Profit for Oncology & Multispecialty was $366 million, above the average estimate of $353.98 million [4] - Adjusted Operating Profit for Corporate was -$156 million, better than the estimate of -$180.91 million [4] - Adjusted Operating Profit for North American Pharmaceutical was $872 million, exceeding the average estimate of $855.24 million [4] - Adjusted Operating Profit for Other was $28 million, surpassing the average estimate of $14.6 million [4] Stock Performance - McKesson's shares have returned 3% over the past month, outperforming the Zacks S&P 500 composite's return of 0.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Viewpoint - McKesson Corporation has raised its fiscal 2026 profit forecast, driven by anticipated strong growth in its oncology and specialty drug distribution sectors [1] Company Summary - McKesson Corporation is focusing on expanding its oncology and specialty drug distribution businesses, which are expected to contribute significantly to its profit growth in fiscal 2026 [1]

分组1 - McKesson reported quarterly earnings of $9.34 per share, exceeding the Zacks Consensus Estimate of $9.31 per share, and up from $8.03 per share a year ago, representing an earnings surprise of +0.35% [1] - The company achieved revenues of $106.16 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.47%, compared to $95.29 billion in the same quarter last year [2] - McKesson has outperformed the S&P 500 with a share price increase of about 3.8% since the beginning of the year, while the S&P 500 gained 1.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $11.19 on revenues of $101.62 billion, and for the current fiscal year, it is $38.63 on revenues of $408.09 billion [7] - The Medical - Dental Supplies industry, to which McKesson belongs, is currently ranked in the top 40% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Financial Data and Key Metrics Changes - The company reported consolidated revenues of $106.2 billion, an increase of 11% year-over-year, driven by broad-based growth across the business [21][28] - Adjusted earnings per diluted share increased 16% to $9.34, reflecting strong operational performance [22][28] - Operating profit rose 13% year-over-year to $1.7 billion, supported by increased demand for access solutions and strong growth in specialty distribution [22][28] Business Line Data and Key Metrics Changes - North American Pharmaceutical revenues increased by 9% to $88.3 billion, driven by higher prescription volumes and specialty product distribution strength [23][28] - Oncology and Multispecialty segment revenues surged 37% to $13 billion, with operating profit increasing 57% to $366 million, aided by provider growth and acquisitions [24][28] - Prescription Technology Solutions revenues grew by 9% to $1.5 billion, with operating profit rising 18% to $277 million, driven by demand for access solutions [25][28] Market Data and Key Metrics Changes - GLP-1 distribution revenues reached $14 billion, up $3 billion or 26% compared to the prior year, indicating strong market demand [23][28] - The company anticipates revenue growth of 12%-16% and operating profit growth of 13%-17% for fiscal 2026, reflecting sustained momentum across core businesses [28][29] Company Strategy and Development Direction - The company is focused on two strategic growth pillars: Oncology and Multispecialty, and Biopharma Services, aiming to leverage its scale and connectivity in the community space [7][9] - Investments are being made in technology and automation to enhance operational efficiency and improve patient access to medications [11][12] - The company is progressing with the separation of its Medical-Surgical business, targeting an IPO by the second half of calendar 2027 [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to extend momentum and execute against strategic priorities, highlighting a strong financial position and disciplined capital allocation [18][36] - The operating environment is viewed as navigable despite regulatory changes, with ongoing engagement with lawmakers to advocate for patient access and community care [68][69] Other Important Information - The company completed the divestiture of its Norwegian operations, marking the final step in its exit from Europe, which is expected to contribute approximately $1 billion in revenue for fiscal 2026 [20][28] - Free cash flow for the quarter was $1.1 billion, with a total of $9.6 billion for the trailing 12 months, demonstrating strong operational performance [26][27] Q&A Session Summary Question: Can you discuss the specific investments in technology and automation? - Management highlighted investments in AI and automation to improve workflows, resulting in increased productivity during the annual verification season [39][40] Question: What is the long-term opportunity to improve margins in the segment? - Management noted that half of the segment's revenue is related to third-party logistics, with ongoing automation expected to enhance margins [43][44] Question: Any nuances to consider for fiscal 2027 guidance? - Management indicated stable utilization trends and strong specialty distribution growth, with a focus on operational efficiency as positive indicators for future performance [50][51] Question: What is driving the margin improvement in Oncology and Multispecialty? - Management attributed margin improvements to provider additions and growth in specialty oncology products, with ongoing automation efforts expected to further enhance margins [55][57] Question: How is the company navigating regulatory changes? - Management expressed confidence in navigating the regulatory landscape, emphasizing constructive discussions with manufacturing partners regarding pricing strategies [68][69]

Financial Data and Key Metrics Changes - The company reported consolidated revenues of $106.2 billion, an increase of 11% year-over-year, driven by broad-based growth across the business [21][28] - Adjusted earnings per diluted share increased 16% to $9.34, reflecting strong operational performance [22][28] - Operating profit rose 13% year-over-year to $1.7 billion, supported by increased demand for access solutions and strong growth in specialty distribution [22][28] Business Line Data and Key Metrics Changes - North American pharmaceutical revenues increased by 9% to $88.3 billion, driven by higher prescription volumes and specialty product distribution strength [23][28] - Oncology and multispecialty segment revenues surged by 37% to $13 billion, with operating profit increasing by 57% to $366 million, aided by provider growth and acquisitions [24][28] - Prescription technology solutions revenues grew by 9% to $1.5 billion, with operating profit rising 18% to $277 million, driven by demand for access solutions [25][28] - Medical-surgical solutions revenues increased by 1% to $3 billion, but operating profit decreased by 10% to $265 million due to lower volumes [25][28] Market Data and Key Metrics Changes - GLP-1 distribution revenues reached $14 billion, up $3 billion or 26% compared to the prior year, indicating strong demand in the market [23][28] - The company continues to see stable utilization trends and strong specialty distribution growth across its North American pharmaceutical segment [29][30] Company Strategy and Development Direction - The company is focused on two strategic growth pillars: oncology and multispecialty, and biopharma services, leveraging its scale and leadership to meet evolving market needs [7][8] - Investments are being made in technology and automation to enhance operational efficiency and improve patient access to medications [11][12] - The company is progressing with the separation of its medical-surgical business, aiming for an IPO by the second half of calendar 2027 [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to extend momentum and execute against strategic priorities, raising full-year EPS guidance to a range of $38.80-$39.20, reflecting 17%-19% growth [5][28] - The company anticipates revenue growth of 12%-16% and operating profit growth of 13%-17% for the full year, supported by strong third-quarter performance [28][29] - Management highlighted the importance of community-based care and the role of advocacy in expanding patient access [9][10] Other Important Information - The company completed the divestiture of its Norwegian operations, marking the final step in its exit from Europe, which is expected to contribute approximately $1 billion in revenue for fiscal 2026 [20][28] - Free cash flow for the quarter was $1.1 billion, with a total of $9.6 billion for the trailing 12 months, demonstrating strong operational performance [26][27] Q&A Session Summary Question: Can you discuss the specific investments in technology and automation? - Management highlighted investments in AI and automation to improve workflows, resulting in increased productivity during the annual verification season [38][39] Question: What are the long-term opportunities for margin improvement in the segment? - Management noted that half of the segment's revenue is related to third-party logistics, with ongoing automation expected to improve margins [43][44] Question: Any nuances to consider for fiscal 2027 guidance? - Management indicated stable utilization trends and strong specialty distribution growth, with operational efficiency gains supporting positive growth [48][50] Question: What is driving the margin improvement in oncology and multispecialty? - Management attributed margin improvements to provider additions and continued growth in specialty oncology products [55][57] Question: How is the company navigating the regulatory environment? - Management expressed confidence in navigating the regulatory landscape, emphasizing constructive conversations with manufacturing partners [66][69]